ArticleCancer imaging : the official publication of the International Cancer Imaging Society2026
Evaluation of RECIST v1.1 for predicting overall survival in sarcoma patients with pulmonary metastasis.
Article in Cancer imaging : the official publication of the International Cancer Imaging Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeResponse assessment in the treatment of metastatic sarcoma primarily depends on imaging, as no established clinical or serological biomarkers reliably predict survival outcomes. This study evaluates the utility of Response Evaluation Criteria in Solid Tumors (RECIST v1.1) in predicting overall survival (OS) in sarcoma patients with pulmonary metastases.
methodsWe selected consecutive study subjects from a prospective registry based on the following criteria: (1) available CT imaging at first diagnosis of pulmonary metastases from sarcoma, (2) available follow-up CT imaging within 16 weeks of systemic therapy initiation, (3) documentation of OS. Volumetric segmentation of up to 5 lung metastases was performed over time. Progressive disease (PD) was defined as increase of the unidimensional sum of lesions ≥ 20% or appearance of new metastases according to RECIST v1.1. Kaplan-Meier survival analyses were performed. P values < 0.05 were considered statistically significant.
resultsNinety-two patients were included (median age: 58 years; 50% female). Average time of follow-up CT was 67 days after baseline imaging. Patients with PD on first follow-up imaging (n = 24; 26%) showed significantly shorter OS (13.9 months vs. 29.3 months; p = 0.014). The unidimensional growth threshold of 20% proposed by RECIST did not stratify OS (14.6 months vs. 26.8 months, p = 0.221). The appearance of new metastases (n = 16; 17%) indicated significantly shorter OS (7.8 months vs. 27.0 months; p < 0.001) and was frequently observed even in patients with decreasing size of existing metastases (n = 7; 8%).
conclusionImaging progression patterns of pulmonary metastatic sarcoma demonstrate distinct associations with OS, highlighting the need for sarcoma-specific adaptations to established response criteria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.